Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - Johnston, S RD; Toi, M; O'Shaughnessy, J; monarchE Committee Members (Lancet Oncol, 2023)